Italfarmaco Secures Managed Entry Agreement for Duvyzat in Georgia
MILAN, Italy, July 31, 2026 talfarmaco S.p.A. announced a managed entry agreement with the Georgian Ministry of Health to...
ADC AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery FDA fda approval FDA clearance Gene Therapy healthcare technology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
MILAN, Italy, July 31, 2026 talfarmaco S.p.A. announced a managed entry agreement with the Georgian Ministry of Health to...
MILAN, Italy & HYOGO, Japan | December 24, 2025 — Italfarmaco and JCR Pharmaceuticals have announced a landmark commercialisation...
